RxDoctor Payments Data

Brittany Bowerman, APRN

Family · Omaha, NENPI 1760124747

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 35 payments — averaging $49.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$656
  • Neurocrine Biosciences, Inc.$332
  • Otsuka America Pharmaceutical, Inc.$232
  • AbbVie$221
  • Amgen$134
  • Bayer$30
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$63,329
Medicare patients
237
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole48$42,693
OzempicSemaglutide15$15,286
EliquisApixaban27$12,059
JardianceEmpagliflozin12$8,242
Paliperidone ErPaliperidone13$7,038
MyrbetriqMirabegron20$6,379
BelsomraSuvorexant26$4,719
Quetiapine Fumarate ErQuetiapine Fumarate38$4,292
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen127$3,885
Potassium Chloride53$3,337
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$3,260
OxycontinOxycodone Hcl17$3,222
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,173
Fentanyl25$2,803
Gabapentin121$2,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$232$42,69348 claims
Novo NordiskOzempic$29$15,28615 claims
Boehringer IngelheimJardiance$13$8,24212 claims
MerckBelsomra$13$4,71926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.

Other family in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →